Hepatic decompensating events in patients with type 2 diabetes, with and without obesity (Comparison between propensity-score matched cohorts)

of cases (overall risk) # of cases (overall risk)

Comparison

Exposure

Cohort size	cohort	cohort	(Exposure cohort)	(Comparison cohort)		HR (95% CI)
	Obesity					
21,959	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	176 (0.80%)	867 (3.95%)	 ■ 	0.19 (0.16–0.23)
21,097	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	707 (3.35%)	786 (3.73%)	 = 	0.91 (0.82–1.00)
42,291	GLP-1RA(+)DDP-4(-)	DPP-4(+)GLP-1RA(-)	1,166 (2.76%)	1,572 (3.72%)	 ■ 	0.68 (0.63-0.73)
19,007	GLP-1RA(+)SGLT2(-)	SGLT2(+)GLP-1RA(-)	578 (3.04%)	591 (3.11%)	 ■ 	0.93 (0.83–1.04)
43,523	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	1,163 (2.67%)	1,595 (3.67%)	 ■ 	0.68 (0.63-0.73)
19,388	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	507 (2.62%)	567 (2.92%)	├ ■ ┤	0.83 (0.73-0.93)
	No obesity					
24,392	GLP-1RA(+)Insulin(-)	Insulin(+)GLP-1RA(-)	125 (0.51%)	821 (3.37%)	⊢■ ⊣	0.15 (0.12–0.18)
24,945	GLP-1RA(+)Metformin(-)	Metformin(+)GLP-1RA(-)	649 (2.60%)	720 (2.89%)	= 	0.92 (0.83–1.02)
59,166	GLP-1RA(+)DDP-4(-)	DPP-4(+)GLP-1RA(-)	1,190 (2.01%)	1,696 (2.87%)	I ≡I	0.65 (0.61–0.71)
33,906	GLP-1RA(+)SGLT2(-)	SGLT2(+)GLP-1RA(-)	727 (2.14%)	871 (2.57%)	 ■ 	0.80 (0.73-0.88)
49,323	GLP-1RA(+)SU(-)	SU(+)GLP-1RA(-)	1,048 (2.13%)	1,449 (2.94%)	H ≡ H	0.69 (0.64–0.75)
42,717	GLP-1RA(+)TZD(-)	TZD(+)GLP-1RA(-)	866 (2.03%)	1,013 (2.37%)	 ■ 	0.82 (0.75–0.90)
					0.20 0.30 0.500.70 1.0 2.0 Hazard Ratio (HR)	3.004.0